Action Tiziana Life Sciences - TLSA

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

1,69

Prix Achat

1,77

Prix Vente

1,80

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

1,69

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

TLSA - Frequently Asked Questions (FAQ)

What is the current Tiziana Life Sciences share price?

The current share price of Tiziana Life Sciences is US$ 1,69

What is the 1 year trading range for Tiziana Life Sciences share price?

Tiziana Life Sciences has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,14M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,92M
KZIAKazia Therapeutics Ltd	US$ 1,1899 (40,80%)	4,5M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	570,43k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,54M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,13M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	332,1k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	618,03M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	476,73M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	333,91M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	140,23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	140,05M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Tiziana Life Sciences Ltd (TLSA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

TLSA Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

TLSA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Tiziana Life Sciences Ltd (TLSA) Cours

Tiziana Life Sciences Ltd (TLSA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

TLSA Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

TLSA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR